PMID- 31989258
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 1432-1068 (Electronic)
IS  - 1633-8065 (Linking)
VI  - 30
IP  - 5
DP  - 2020 Jul
TI  - Umbilical cord-derived mesenchymal stem cells for treating osteoarthritis of the 
      knee: a single-arm, open-label study.
PG  - 799-807
LID - 10.1007/s00590-020-02630-5 [doi]
AB  - BACKGROUND: Despite being a common cause of quality-of-life impairment, there are 
      no efficacious therapies that could prevent the progression of knee 
      osteoarthritis (KOA). We conducted an open-label trial of human umbilical 
      cord-derived mesenchymal stem cells (hUC-MSCs) and hyaluronic acid (HA) for 
      treating KOA. METHODS: This open-label study was conducted from July 2015 to 
      December 2018 at Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Patients 
      diagnosed with KOA were injected three times, comprising of 10 x 106 units of 
      hUC-MSCs in 2-ml secretome implantation and 2-ml hyaluronic acid (HA) injection 
      in the first week, followed with 2-ml HA injection twice in the second and third 
      week. RESULTS: Twenty-nine subjects (57 knees) were recruited. Seventeen (58.6%) 
      subjects were male, and the mean age was 58.3 +/- 9.6 years. Thirty-three (57.9%) 
      knees were classified into Kellgren-Lawrence grade I-II KOA (mild OA). hUC-MSCs 
      significantly decreased pain measured by visual analogue scale in severe KOA from 
      initial to 6th month follow-up [5 +/- 2.97 to 3.38 +/- 2.44 (p = 0.035)]. The 
      International Knee Documentation Committee score significantly increased at 6th 
      month follow-up (53.26 +/- 16.66 to 65.49 +/- 13.01, p < 0.001, in subjects with 
      grade I-II and 48.84 +/- 18.41 to 61.83 +/- 18.83, p = 0.008, in subjects with severe 
      KOA). The Western Ontario and McMaster Universities Osteoarthritis decreased 
      significantly in both groups from initial to 6th month follow-up (from 
      22.55 +/- 15.94 to 13.23 +/- 10.29, p = 0.003, and from 27.57 +/- 15.99 to 
      17.92 +/- 19.1, p = 0.003, in those with mild and severe KOA, respectively). 
      CONCLUSIONS: hUC-MSCs could be a potentially new regenerative treatment for KOA. 
      The maximum effect of hUC-MSCs was achieved after 6 months of injection. LEVEL OF 
      EVIDENCE: Therapeutic level II.
FAU - Dilogo, Ismail Hadisoebroto
AU  - Dilogo IH
AUID- ORCID: 0000-0002-6202-0918
AD  - Department of Orthopaedics and Traumatology, Cipto Mangunkusumo General Hospital, 
      Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. 
      ismailortho@gmail.com.
AD  - Stem Cell Medical Technology Integrated Medical Service Unit, Cipto Mangunkusumo 
      General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. 
      ismailortho@gmail.com.
AD  - Stem Cell and Tissue Engineering Research Center, IMERI, Faculty of Medicine, 
      Universitas Indonesia, Jakarta, Indonesia. ismailortho@gmail.com.
FAU - Canintika, Anissa Feby
AU  - Canintika AF
AD  - Department of Orthopaedics and Traumatology, Cipto Mangunkusumo General Hospital, 
      Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
FAU - Hanitya, Alberto Lastiko
AU  - Hanitya AL
AD  - Department of Orthopaedics and Traumatology, Cipto Mangunkusumo General Hospital, 
      Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
FAU - Pawitan, Jeanne Adiwinata
AU  - Pawitan JA
AD  - Stem Cell Medical Technology Integrated Medical Service Unit, Cipto Mangunkusumo 
      General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
AD  - Stem Cell and Tissue Engineering Research Center, IMERI, Faculty of Medicine, 
      Universitas Indonesia, Jakarta, Indonesia.
AD  - Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta, 
      Indonesia.
FAU - Liem, Isabella Kurnia
AU  - Liem IK
AD  - Stem Cell Medical Technology Integrated Medical Service Unit, Cipto Mangunkusumo 
      General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
AD  - Stem Cell and Tissue Engineering Research Center, IMERI, Faculty of Medicine, 
      Universitas Indonesia, Jakarta, Indonesia.
AD  - Department of Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, 
      Indonesia.
FAU - Pandelaki, Jacub
AU  - Pandelaki J
AD  - Department of Radiology, Cipto Mangunkusumo General Hospital, Faculty of 
      Medicine, Universitas Indonesia, Jakarta, Indonesia.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20200127
PL  - France
TA  - Eur J Orthop Surg Traumatol
JT  - European journal of orthopaedic surgery & traumatology : orthopedie traumatologie
JID - 9518037
RN  - 0 (Viscosupplements)
RN  - 9004-61-9 (Hyaluronic Acid)
SB  - IM
MH  - Aged
MH  - Arthralgia/etiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hyaluronic Acid/*therapeutic use
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Middle Aged
MH  - Osteoarthritis, Knee/complications/diagnostic imaging/*therapy
MH  - Pain Measurement
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Umbilical Cord/cytology
MH  - Viscosupplements/*therapeutic use
OTO - NOTNLM
OT  - Mesenchymal stem cells
OT  - Osteoarthritis
OT  - Umbilical cord
EDAT- 2020/01/29 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/01/29 06:00
PHST- 2019/10/31 00:00 [received]
PHST- 2020/01/20 00:00 [accepted]
PHST- 2020/01/29 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/01/29 06:00 [entrez]
AID - 10.1007/s00590-020-02630-5 [pii]
AID - 10.1007/s00590-020-02630-5 [doi]
PST - ppublish
SO  - Eur J Orthop Surg Traumatol. 2020 Jul;30(5):799-807. doi: 
      10.1007/s00590-020-02630-5. Epub 2020 Jan 27.